Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Serrano

Pickerington, OH Medical Doctor

NPI 1508852468 CMS profile 204380

475 Hill Rd N, Pickerington, OH 43147

Open in the dashboard

General payments

$10,814

730 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Serrano of Pickerington, OH is reported in the CMS Open Payments database as having received $10,814 across 730 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,594 86
2024 General $1,523 90
2023 General $1,448 97
2022 General $1,780 142
2021 General $2,164 147
2020 General $1,259 88
2019 General $1,047 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Serrano
  • Ohio median
  • Middle half of Ohio
  • National median

In program year 2025, general payments to Eric Serrano were reported at $1,594. Among 40,289 Ohio profiles paid that year, the median was $159 and the middle half received between $47 and $569.

Show as a table
Year Eric Serrano Ohio median Middle half National median
2019 $1,047 $166 $50–$652 $163
2020 $1,259 $110 $33–$367 $114
2021 $2,164 $125 $35–$432 $132
2022 $1,780 $141 $41–$498 $149
2023 $1,448 $150 $43–$522 $160
2024 $1,523 $153 $45–$543 $164
2025 $1,594 $159 $47–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,795 138 payments
  2. AstraZeneca Pharmaceuticals LP $1,760 91 payments
  3. Novo Nordisk Inc $551 47 payments
  4. IBSA Pharma Inc. $529 32 payments
  5. Abbott Laboratories $392 31 payments
  6. Bausch Health US, LLC $372 26 payments
  7. Biohaven Pharmaceuticals, Inc. $339 29 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $337 27 payments
  9. Merck Sharp & Dohme Corporation $328 33 payments
  10. Pfizer Inc. $323 29 payments
  11. Other $4,090 247 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,790 725 payments
  2. Education $24 5 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $969 49 payments
  2. UBRELVY $818 62 payments
  3. NURTEC ODT $575 49 payments
  4. QULIPTA $484 38 payments
  5. CREON $465 31 payments
  6. Tirosint $463 28 payments
  7. Ozempic $444 38 payments
  8. Licart $412 24 payments
  9. XYOSTED $347 19 payments
  10. LINZESS $317 26 payments
  11. Other $9,059 650 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

241

Median for Specialist: 51

Drug cost

$27,291

Median for Specialist: $1,236

Branded share of claims

58.9%

Median for Specialist: 21.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 12 $13,238
Np Thyroid Thyroid,pork Brand 52 $5,014
Progesterone Progesterone, Micronized Brand 46 $3,283
Armour Thyroid Thyroid,pork Brand 21 $2,745
Liothyronine Sodium Generic 11 $915
Testosterone Cypionate Generic 13 $798
Levothyroxine Sodium Generic 22 $612
Estradiol Generic 24 $458
Prednisone Generic 17 $110
Bupropion Xl Bupropion Hcl Brand 11 $61

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,049 Part D prescribers listed as Specialist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$147 — —
CYCLOSET
$115 — —
XYOSTED
$101 — —
Tlando
$84 — —
Korlym
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

730 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record